Do analysts recommend CLNN or SBTX?

Clene presently has a consensus price target of $34.00, indicating a potential upside of 745.77%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CLNN or LFCR more profitable?

Lifecore Biomedical has a net margin of -29.93% compared to Clene's net margin of -20,063.96%. Company Net Margins Return on Equity Return on Assets Clene -20,063.96% N/A -137.04% Lifecore Biomedical -29.93% N/A -16.16%

Does the media favor CLNN or LFCR?

In the previous week, Clene had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for Clene and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.04 beat Clene's score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, IMUX or CLNN?

Clene has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Clene $197K 262.20 -$26.17M -$3.50 N/A

Is IMUX or CLNN more profitable?

Immunic has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Clene -20,063.96% N/A -137.04%

Does the media refer more to IMUX or CLNN?

In the previous week, Immunic had 7 more articles in the media than Clene. MarketBeat recorded 11 mentions for Immunic and 4 mentions for Clene. Clene's average media sentiment score of 0.94 beat Immunic's score of 0.53 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CLNN or MENS?

Clene presently has a consensus price target of $34.00, suggesting a potential upside of 745.77%. Given Clene's stronger consensus rating and higher probable upside, research analysts plainly believe Clene is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CLNN or MENS?

Jyong Biotech has lower revenue, but higher earnings than Clene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $197K 262.20 -$26.17M -$3.50 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is CLNN or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Company Net Margins Return on Equity Return on Assets Clene -20,063.96% N/A -137.04% Jyong Biotech N/A N/A N/A

Is NRXP or CLNN more profitable?

NRx Pharmaceuticals has a net margin of -691.81% compared to Clene's net margin of -20,063.96%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Clene -20,063.96% N/A -137.04%

Does the media prefer NRXP or CLNN?

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Clene. MarketBeat recorded 13 mentions for NRx Pharmaceuticals and 4 mentions for Clene. Clene's average media sentiment score of 0.94 beat NRx Pharmaceuticals' score of 0.70 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Clene (CLNN) Competitors

$4.02 +0.74 (+22.56%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 -0.05 (-1.37%)

As of 07:58 PM Eastern

Compare

CLNN vs. SBTX, LFCR, IMUX, MENS, and NRXP

Should you buy Clene stock or one of its competitors? Clene's main competitors and comparable companies include Silverback Therapeutics (SBTX), Lifecore Biomedical (LFCR), Immunic (IMUX), Jyong Biotech (MENS), and NRx Pharmaceuticals (NRXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clene compare to Silverback Therapeutics?

Clene (NASDAQ:CLNN) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Clene had 4 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for Clene and 0 mentions for Silverback Therapeutics. Clene's average media sentiment score of 0.94 beat Silverback Therapeutics' score of 0.00 indicating that Clene is being referred to more favorably in the media.

Company	Overall Sentiment
Clene	Positive
Silverback Therapeutics	Neutral

23.3% of Clene shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Clene presently has a consensus price target of $34.00, indicating a potential upside of 745.77%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silverback Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Clene has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Clene has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$197K	262.20	-$26.17M	-$3.50	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Clene beats Silverback Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Clene compare to Lifecore Biomedical?

Clene (NASDAQ:CLNN) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Clene had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for Clene and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.04 beat Clene's score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Clene currently has a consensus target price of $34.00, indicating a potential upside of 745.77%. Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 57.00%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Clene is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifecore Biomedical has a net margin of -29.93% compared to Clene's net margin of -20,063.96%.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Clene has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$197K	262.20	-$26.17M	-$3.50	N/A
Lifecore Biomedical	$128.87M	1.22	-$40.50M	-$1.07	N/A

23.3% of Clene shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Lifecore Biomedical beats Clene on 8 of the 15 factors compared between the two stocks.

How does Clene compare to Immunic?

Immunic (NASDAQ:IMUX) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Immunic presently has a consensus target price of $47.25, indicating a potential upside of 355.64%. Clene has a consensus target price of $34.00, indicating a potential upside of 745.77%. Given Clene's higher probable upside, analysts clearly believe Clene is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Clene has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Clene	$197K	262.20	-$26.17M	-$3.50	N/A

In the previous week, Immunic had 7 more articles in the media than Clene. MarketBeat recorded 11 mentions for Immunic and 4 mentions for Clene. Clene's average media sentiment score of 0.94 beat Immunic's score of 0.53 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.8% of Immunic shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunic has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Immunic has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Clene	-20,063.96%	N/A	-137.04%

Summary

Immunic and Clene tied by winning 8 of the 16 factors compared between the two stocks.

How does Clene compare to Jyong Biotech?

Clene (NASDAQ:CLNN) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Clene presently has a consensus price target of $34.00, suggesting a potential upside of 745.77%. Given Clene's stronger consensus rating and higher probable upside, research analysts plainly believe Clene is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.3% of Clene shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jyong Biotech has lower revenue, but higher earnings than Clene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$197K	262.20	-$26.17M	-$3.50	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

In the previous week, Clene had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Clene and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Clene's score of 0.94 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Clene	Positive
Jyong Biotech	Very Positive

Clene has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

Jyong Biotech has a net margin of 0.00% compared to Clene's net margin of -20,063.96%.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Jyong Biotech	N/A	N/A	N/A

Summary

Clene beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Clene compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Clene. MarketBeat recorded 13 mentions for NRx Pharmaceuticals and 4 mentions for Clene. Clene's average media sentiment score of 0.94 beat NRx Pharmaceuticals' score of 0.70 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$3.39M	43.37	-$28.62M	-$0.55	N/A
Clene	$197K	262.20	-$26.17M	-$3.50	N/A

NRx Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 914.71%. Clene has a consensus target price of $34.00, suggesting a potential upside of 745.77%. Given NRx Pharmaceuticals' higher possible upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

NRx Pharmaceuticals has a net margin of -691.81% compared to Clene's net margin of -20,063.96%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Clene	-20,063.96%	N/A	-137.04%

Summary

Clene beats NRx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Clene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLNN vs. The Competition

Export

Metric	Clene	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.65M	$12.42B	$7.16B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-1.15	792.11	273.41	25.34
Price / Sales	262.20	763.33	674.92	98.63
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	-2.48	10.40	10.38	6.20
Net Income	-$26.17M	$2.83B	$3.49B	$358.18M
7 Day Performance	11.05%	-3.27%	-2.20%	-1.61%
1 Month Performance	-2.90%	0.84%	-0.38%	-3.62%
1 Year Performance	-35.68%	3.65%	19.16%	5.95%

Clene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLNN Clene	2.0581 of 5 stars	$4.02 +22.6%	$34.00 +745.8%	-43.4%	$51.65M	$197K	N/A	100	News Coverage High Trading Volume
SBTX Silverback Therapeutics	N/A	$4.76 -5.9%	N/A	-52.5%	$171.64M	N/A	N/A	83	High Trading Volume
LFCR Lifecore Biomedical	1.56 of 5 stars	$4.25 +3.2%	$6.50 +52.9%	-43.5%	$155.96M	$128.87M	N/A	690	Positive News
IMUX Immunic	2.9468 of 5 stars	$11.23 -1.7%	$47.25 +320.7%	+41.4%	$155.81M	N/A	N/A	70
MENS Jyong Biotech	N/A	$2.08 +4.5%	N/A	-96.6%	$151.29M	N/A	N/A	31	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLNN) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clene (CLNN) Competitors

CLNN vs. SBTX, LFCR, IMUX, MENS, and NRXP

How does Clene compare to Silverback Therapeutics?

Summary

How does Clene compare to Lifecore Biomedical?

Summary

How does Clene compare to Immunic?

Summary

How does Clene compare to Jyong Biotech?

Summary

How does Clene compare to NRx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clene (CLNN) Competitors

CLNN vs. SBTX, LFCR, IMUX, MENS, and NRXP

How does Clene compare to Silverback Therapeutics?

Does the media refer more to CLNN or SBTX?

Do insiders and institutionals have more ownership in CLNN or SBTX?

Do analysts recommend CLNN or SBTX?

Is CLNN or SBTX more profitable?

Which has more risk and volatility, CLNN or SBTX?

Which has stronger valuation & earnings, CLNN or SBTX?

Summary

How does Clene compare to Lifecore Biomedical?

Does the media favor CLNN or LFCR?

Which has more risk and volatility, CLNN or LFCR?

Do analysts rate CLNN or LFCR?

Is CLNN or LFCR more profitable?

Which has stronger earnings & valuation, CLNN or LFCR?

Do insiders & institutionals believe in CLNN or LFCR?

Summary

How does Clene compare to Immunic?

Do analysts prefer IMUX or CLNN?

Which has higher earnings and valuation, IMUX or CLNN?

Does the media refer more to IMUX or CLNN?

Do insiders and institutionals hold more shares of IMUX or CLNN?

Which has more volatility & risk, IMUX or CLNN?

Is IMUX or CLNN more profitable?

Summary

How does Clene compare to Jyong Biotech?

Do analysts prefer CLNN or MENS?

Do insiders & institutionals have more ownership in CLNN or MENS?

Which has higher earnings and valuation, CLNN or MENS?

Does the media favor CLNN or MENS?

Which has more volatility and risk, CLNN or MENS?

Is CLNN or MENS more profitable?

Summary

How does Clene compare to NRx Pharmaceuticals?

Does the media prefer NRXP or CLNN?

Which has better valuation and earnings, NRXP or CLNN?

Which has more volatility & risk, NRXP or CLNN?

Do insiders and institutionals have more ownership in NRXP or CLNN?

Do analysts prefer NRXP or CLNN?

Is NRXP or CLNN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools